A nomogram for predicting the HER2 status of circulating tumor cells and survival analysis in HER2-negative breast cancer

BACKGROUND: In breast cancer patients with HER2-negative tumors (tHER2-), HER2-positive CTCs (cHER2+) were associated with promising efficacy of HER2-targeted therapy, but controversy has persisted over its prognostic effect. We developed a model including clinicopathologic parameters/blood test var...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yuqin, Li, Liudan, Tian, Wenjing, Qiao, Zhen, Qin, Qi, Su, Liqian, Li, Peiqiu, Chen, Weirong, Zhao, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811813/
https://www.ncbi.nlm.nih.gov/pubmed/36620609
http://dx.doi.org/10.3389/fonc.2022.943800

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811813/
https://www.ncbi.nlm.nih.gov/pubmed/36620609
http://dx.doi.org/10.3389/fonc.2022.943800

Ejemplares similares